A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PS / pulmonary surfactant

[Related PubMed/MEDLINE]
Total Number of Papers: 156
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PS  (>> Co-occurring Abbreviation)
Long Form:   pulmonary surfactant
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Interaction of nano carbon particles and anthracene with pulmonary surfactant: The potential hazards of inhaled nanoparticles. NCPs, NPs, PAHs
2018 Aggregation State of Metal-Based Nanomaterials at the Pulmonary Surfactant Film Determines Biophysical Inhibition. CDS, MNMs
2018 Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. PHT, rh-insulin
2018 Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study. RDS
2018 GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway. ALI, ATII, GLP-1, LPS, SP-A, TTF-1
2018 Knockout of microRNA‑26a promotes lung development and pulmonary surfactant synthesis. AECIIs, miR
2018 Polarized light microscopy reveals physiological and drug-induced changes in surfactant membrane assembly in alveolar type II pneumocytes. LBs, PL, PM
2018 Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins. SPs
2018 Pulmonary surfactant-associated proteins and inflammatory factors in obstructive sleep apnea. AHI, BALF, OSA
10  2018 Role of Lipid Coating in the Transport of Nanodroplets across the Pulmonary Surfactant Layer Revealed by Molecular Dynamics Simulations. ---
11  2018 Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy. siRNA, SP-B
12  2018 Synthesis of phosphatidylcholine in rats with oleic acid-induced pulmonary edema and effect of exogenous pulmonary surfactant on its De Novo synthesis. ALI, ARDS, BALF, cpm, DSPC, LT, OA, OA-PS, PC, PE, SR, TP, TPL
13  2018 Understanding the principle biophysics concepts of pulmonary surfactant in health and disease. ---
14  2018 [A review on neonatal acute respiratory distress syndrome]. ARDS
15  2018 [Clinical effect of bubble nasal continuous positive airway pressure versus conventional nasal continuous positive airway pressure in respiratory support for preterm infants with neonatal respiratory distress syndrome]. Bn-CPAP, BPD, nCPAP, NRDS, ROP
16  2018 [Comparison of clinical efficacy of two noninvasive respiratory support therapies for respiratory distress syndrome in very low birth weight preterm infants]. HHHFNC, NIPPV, RDS, VLBW
17  2017 Clinical effects of pulmonary surfactant in combination with nasal continuous positive airway pressure therapy on neonatal respiratory distress syndrome. nCPAP, NRDS
18  2017 Effect of pulmonary surfactant combined with mechanical ventilation on oxygenation functions and expressions of serum transforming growth factor-beta1 (TGF-beta1) and bone morphogenetic protein 7 (BMP-7) of neonatal respiratory distress syndrome. ARDS, BMP-7, CMV, ELISA, NRDS, OI, RI, TGF-beta1
19  2017 Efficacy study of pulmonary surfactant combined with assisted ventilation for acute respiratory distress syndrome management of term neonates. RDS
20  2017 Human amniotic membrane as newly identified source of amniotic fluid pulmonary surfactant. HAM
21  2017 Pulmonary surfactant synthesis in miRNA-26a-1/miRNA-26a-2 double knockout mice generated using the CRISPR/Cas9 system. AECIIs, RDS
22  2017 Unveiling the Molecular Structure of Pulmonary Surfactant Corona on Nanoparticles. NPs
23  2017 [Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants]. BPD, NRDS, OI, VLBW
24  2016 Development of a Synthetic Surfactant Using a Surfactant Protein-C Peptide Analog: In Vitro Studies of Surface Physical Properties. PNBS, SP, SPa-C, sSP-C PS, STs
25  2016 Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells. NPs, ZnO NWs
26  2016 Fluidizing and Solidifying Effects of Perfluorooctylated Fatty Alcohols on Pulmonary Surfactant Monolayers. FC, NRDS
27  2016 Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders. ---
28  2016 [Clinical effect of high-frequency oscillatory ventilation combined with pulmonary surfactant in treatment of neonatal severe meconium aspiration syndrome complicated by pulmonary hemorrhage]. HFOV, MAS, NPH, OI
29  2016 [Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome]. MAS
30  2016 [Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis]. BPD, NRDS
31  2016 [Factors influencing the prognosis of patent ductus arteriosus in very low birth weight infants]. PDA, VLBW
32  2016 [Pulmonary surfactant homeostasis associated genetic abnormalities and lung diseases]. AEII
33  2015 A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center. BPD, LISA, MV, nCPAP
34  2015 Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy. RNAi, siRNA
35  2015 Biophysical influence of airborne carbon nanomaterials on natural pulmonary surfactant. CDS, CNM, NP, OELs
36  2015 Delineation of the dynamic properties of individual lipid species in native and synthetic pulmonary surfactants. SP-B
37  2015 Effects of graphene oxide nanosheets on the ultrastructure and biophysical properties of the pulmonary surfactant film. GO
38  2015 Effects of nanoparticles on the mechanical functioning of the lung. ---
39  2015 Efficiency of high-frequency oscillatory ventilation combined with pulmonary surfactant in the treatment of neonatal meconium aspiration syndrome. CMV, HFOV, MAS, NICU, OI
40  2015 Pneumocytes Assemble Lung Surfactant as Highly Packed/Dehydrated States with Optimal Surface Activity. LBPs, LBs
41  2015 Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition. NPs
42  2015 The antimicrobial effect of colistin methanesulfonate on Mycobacterium tuberculosis invitro. CMS, MABA, Mtb, RIF
43  2015 [Clinical efficacy of high-frequency oscillatory ventilation combined with pulmonary surfactant in treatment of neonatal pulmonary hemorrhage]. HFOV, NPH, OI
44  2015 [Clinical features, prevention and treatment of respiratory distress syndrome in neonates of different gestational ages in tertiary hospitals in Northwest China]. GA, RDS
45  2015 [Effects of exogenous pulmonary surfactant on acute lung injury in rats with severe burn-blast combined injury]. ---
46  2015 [Epidemiological survey of neonatal respiratory distress syndrome in part of northwest regions in China]. ART, BW, GA, INSURE, NICUs, RDS
47  2015 [Expression profile of TGF-beta1 and BMP-7 in serum of preterm infants with respiratory distress syndrome]. BMP-7, RDS, TGF-beta1
48  2015 [The clinical comparative study of preterm respiratory distress syndrome and transient tachypnea of newborn]. OI, RDS, TTN
49  2014 Amyloid-beta (1-40) restores adhesion properties of pulmonary surfactant, counteracting the effect of cholesterol. ALI, ARDS
50  2014 Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm infants: a collaborative study of 53 multi-center trials in Korea. EP, LS
51  2014 Nontoxic impact of PEG-coated gold nanospheres on functional pulmonary surfactant-secreting alveolar type II cells. ATII, NPs, PEG
52  2014 Physiological variables affecting surface film formation by native lamellar body-like pulmonary surfactant particles. ALI, LBPs, LBs
53  2014 Promote potential applications of nanoparticles as respiratory drug carrier: insights from molecular dynamics simulations. DPPC, NPs
54  2014 Understanding the mutual impact of interaction between hydrophobic nanoparticles and pulmonary surfactant monolayer. NPs
55  2014 [A population-based epidemiological survey of neonatal respiratory failure in Huai'an City of Jiangsu Province, in 2010]. NRF
56  2014 [Clinical application of nasal intermittent positive pressure ventilation in initial treatment of neonatal respiratory distress syndrome]. nCPAP, NIPPV, NRDS
57  2014 [Clinical effect of endotracheal lavage with porcine pulmonary surfactant in term neonates with severe meconium aspiration syndrome]. MAS, OI
58  2014 [Early use of calf pulmonary surfactant in late preterm and full-term infants with respiratory distress syndrome: a randomized controlled trial]. OI, RDS
59  2014 [Relationship between recovery levels of pulmonary surfactants and lung compliance after whole-lung lavage]. ---
60  2013 Alteration of biophysical activity of pulmonary surfactant by aluminosilicate nanoparticles. MM, NPs
61  2013 Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane. BAM, DLS, DPPC, PM-IRRAS
62  2013 Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: a biophysical approach to disease. MAs, Mtb, TB
63  2013 Pathological study of otitis media with effusion after treatment with intranasal pulmonary surfactant. ABR, ET, OME
64  2013 [Clinical effect of combination therapy with high-frequency oscillation ventilation, pulmonary surfactant and inhaled nitric oxide in the treatment of neonatal hypoxemic respiratory failure]. HFOV, HRF, iNO, OI, PA, PPHN
65  2012 Enhanced pulmonary absorption of recombinant human insulin by pulmonary surfactant and phospholipid hexadecanol tyloxapol through Calu-3 monolayers. PHT, rhINS
66  2012 Expression of SP-C and Ki67 in lungs of preterm infants dying from respiratory distress syndrome. RDS, SP-C
67  2012 Therapeutic effects of inhaling aerosolized surfactant alone or with dexamethasone generated by a novel noninvasive apparatus on acute lung injury in rats. ALI, BALF, DEX, NS
68  2012 [Comparisons of efficacy of different pulmonary surfactants for the treatment of neonatal respiratory distress syndrome]. NRDS
69  2012 [Effect of L-arginine on pulmonary surfactant and alveolar macrophages in rats with pulmonary injury induced by lipopolysaccharide]. ALI, AM, BALF, IL-6, L-Arg, LDH, LPS, NO, SP-A, TNF-alpha, TP
70  2012 [Effect of pulmonary surfactant on Th1/Th2 balance in neonates with respiratory distress syndrome]. IFN-gamma, IL-4, RDS
71  2012 [Efficacy of pulmonary surfactant therapy in neonates with meconium aspiration syndrome: a meta-analysis]. MAS, RCTs
72  2012 [Prospective study on in-hospital mortality and its risk factors in very low birth weight infants requring mechanical ventilation]. CRIB, NICU, SNAPPE-II, VLBWIs
73  2011 Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant. HA-NPs, NPs
74  2011 Intra-amniotic administration of exogenous pulmonary surfactant for improving in lung maturity of fetal rabbits with intrauterine infection caused by premature rupture of membranes. ATII, PROM
75  2011 The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. AT2, BALF, DPPC, PA, TP, TPL
76  2011 [Effects of hydrogen sulfide on pulmonary surfactant in rats with acute lung injury induced by lipopolysccharide]. AECII, ALI, BLAF, CSE, LPS, PPG, SP-A, SP-B, SP-C, TP, TPL
77  2010 Effect of cholesterol on electrostatics in lipid-protein films of a pulmonary surfactant. FM-KPFM
78  2010 Effect of pulmonary surfactant and phospholipid hexadecanol tyloxapol on recombinant human-insulin absorption from intratracheally administered dry powders in diabetic rats. AAC, AKP, BAL, LDH, NAG, PHT, rh-insulin
79  2010 Fluorocarbon-hybrid pulmonary surfactants for replacement therapy--a Langmuir monolayer study. DPPC, LC, LE, PFA, RDS
80  2010 Interfacial reactions of ozone with surfactant protein B in a model lung surfactant system. FIDI, POG, SP-B
81  2010 Vasoactive intestinal peptide induces surfactant protein A expression in ATII cells through activation of PKC/c-Fos pathway. ATII, SP-A, VIP
82  2010 [Effect of NG-nitro-L-arginine on pulmonary surfactant and pulmonary apoptosis in acute lung injury induced by lipopolysaccharide]. ALI, IHC, ISH, L-NA, LPS, SD, SP-A
83  2010 [Effects of positive end expiratory pressure on pulmonary surfactant in patients undergoing one-lung ventilation]. BALF, Sat PC, TP, TPL
84  2009 A quantitative assessment of inhaled drug particle-pulmonary surfactant interaction by atomic force microscopy. AFM, LB
85  2009 Depressed exocytosis and endocytosis of type II alveolar epithelial cells are responsible for the surfactant deficiency in the lung of newborn with congenital diaphragmatic hernia. AECII
86  2009 Effect of SP-C on surface potential distribution in pulmonary surfactant: Atomic force microscopy and Kelvin probe force microscopy study. AFM, BLES, KPFM, SP-C
87  2009 Surfactant therapy for neonatal respiratory distress syndrome: a review of Korean experiences over 17 years. RDS
88  2009 The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery. ---
89  2009 [Effects of high frequency oscillatory ventilation and its combination with pulmonary surfactant treatment on inflammatory response in rabbit lung with inhalation injury]. caspase-1, HFOV, MPO
90  2009 [Exogenous pulmonary surfactant replacement combined with recruitment maneuver in prevention of alveolar derecruitment in rabbits with acute respiratory distress syndrome]. ARDS, Cst, PIP, RM, VALI
91  2009 [Experimental research of prevention and therapy effect of anisodamine on acute respiratory distress syndrome (ARDS)]. ACP, ARDS, FN, LDH, MDA, OA, SOD
92  2009 [Intra-amniotic administration of pulmonary surfactant improves lung ultrastructural pathology and enhances surfactant protein A expression in fetal rabbits with intrauterine infection]. SP-A
93  2009 [Retrospective analysis of elective caesarean section and respiratory distress syndrome in the term neonates]. NICU, OI, PPHN, RDS, VAP
94  2009 [The effects of high frequency oscillatory ventilation (HFOV) and HFOV combined with pulmonary surfactant treatment on lung tissue of rabbits with steam inhalation injury]. CMV, HFOV
95  2008 Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A. BLES, SP-A
96  2008 Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films. I. Micro- and nanostructures of functional pulmonary surfactant films and the effect of SP-A. ---
97  2008 Continuous pulmonary infusion of L-arginine during deep hypothermia and circulatory arrest improves pulmonary surfactant integrity in piglets. DHCA
98  2008 Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation. ARDS, RDS
99  2008 The effect of elevated dietary cholesterol on pulmonary surfactant function in adolescent mice. CS, SAF, sd
100  2008 [Clinical characteristics and outcomes of respiratory distress syndrome in term and late-preterm neonates]. MV, OI, PPHN, RDS, VAP